Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | DAO | P14920 | 2/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | DDO | Q99489 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30960885 | 1.00 | FLT3 (0.44) | FLT3AOC3KDM4EMAPTHPGD | |
| SCHEMBL5850730 | 0.78 | FLT3 (0.48) | FLT3AOC3KDM4EMAPTHPGD | |
| SCHEMBL22747633 | 0.77 | FLT3 (0.41) | FLT3AOC3KDM4EMAPTHPGD | |
| SCHEMBL8161285 | 0.77 | FLT3 (0.36) | FLT3AOC3KDM4EMAPTHPGD | |
| SCHEMBL7325746 | 0.77 | AOC3 (0.52) | FLT3AOC3KDM4EMAPTHPGD | |
| SCHEMBL29079881 | 0.75 | DAO (0.49) | KDM4EMAPTHPGDDAOALDH1A1 | |
| SCHEMBL29079873 | 0.75 | DAO (0.49) | MAPTDAOCYP2C9 | |
| SCHEMBL10923717 | 0.74 | AOC3 (0.48) | FLT3AOC3KDM4EMAPTHPGD | |
| SCHEMBL2125162 | 0.74 | AOC3 (0.48) | FLT3AOC3KDM4EMAPTHPGD | |
| SCHEMBL4288136 | 0.74 | AOC3 (0.48) | FLT3AOC3KDM4EMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117979966-A | Treatment of cancer using SOS1 inhibitors and RAS inhibitors | 锐新医药公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117683049-A | Indole derivatives as RAS inhibitors for the treatment of cancer | 锐新医药公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117597354-A | Method for inhibiting RAS | 综合医院公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-116457358-A | Indole derivatives as RAS inhibitors for the treatment of cancer | 锐新医药公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-116209438-A | Treatment of malignant diseases with SHP2 mutations using SOS1 inhibitors | 锐新医药公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-115894606-A | RAS inhibitors | 锐新医药公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115916194-A | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors | 锐新医药公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115873067-A | RAS inhibitors | 锐新医药公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-114867735-A | RAS inhibitors | 锐新医药公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-114786777-A | RAS inhibitors | 锐新医药公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20070093453-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | ATHEROGENICS, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-7173129-B2 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | ATHERO GENICS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20050049236-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | CRABTREE ACQUISITION CO, LLC | 2005-03-03 | — | — | US | disclosed |
| WO-2004108094-A2 | SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| EP-1054914-A1 | ZWITTERIONIC, NEUTRAL TRANSITION METAL COMPOUND | Basell Polyolefine GmbH (DE) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000035973-A1 | ZWITTERIONIC, NEUTRAL TRANSITION METAL COMPOUND WHICH CONTAINS BORON | TARGOR GMBH (DE) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049236-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | STS, HPSE, SULT1E1 | FLT3 725/4885AOC3 4486/4885KDM4E 2383/4885 |
| US-20070093453-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | STS, HPSE, SULT1E1 | FLT3 725/4885AOC3 4486/4885KDM4E 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.